CTKB

Cytek Biosciences, Inc. (CTKB) - 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for Cytek Biosciences, Inc. for the fiscal year ended December 31, 2025. Cytek is a leading cell analysis solutions company specializing in Full Spectrum Profiling (FSP) technology, which enables high-dimensional single-cell analysis. The company operates globally with manufacturing facilities in the U.S., China, and Singapore, and serves academic, government, biopharmaceutical, and clinical research markets.

Key Financial Metrics

Note: The significant increase in net loss was primarily driven by a $33.1 million valuation allowance recorded against deferred tax assets.

Material Changes vs. Prior Period

• Revenue Composition: While total revenue remained relatively flat, the mix shifted. Product revenue declined 6% to $144.2 million due to a 6% decrease in instrument unit volumes. Conversely, service revenue grew 21% to $57.3 million, driven by an expanding installed base and expiring warranties.
• Margin Compression: Gross margin decreased from 55% to 52%. This was attributed to higher tariff costs and increased production overhead associated with transitioning a manufacturing facility overseas, partially offset by lower material costs.
• Expense Increases: General and Administrative (G&A) expenses surged 37% to $58.9 million, primarily due to higher patent litigation expenses and a lower benefit from a change in estimate regarding a royalty settlement liability. Research and Development (R&D) expenses decreased 7% to $36.5 million as the company streamlined activities.
• Tax Provision: The company recorded a $33.6 million valuation allowance against deferred tax assets due to uncertainty regarding the realization of future tax benefits, a significant non-cash charge impacting the bottom line.

Guidance, Outlook, and Risks

Management Commentary: Management expects expenses to increase substantially in the future to support growth strategies, including hiring, commercial infrastructure expansion, and R&D. The company anticipates that recurring revenue from reagents and services will become an increasingly important contributor as the installed base grows.

Key Risks and Contingencies:

• Legal Proceedings: The company is defending against a patent infringement lawsuit filed by Beckman Coulter, Inc. in August 2024, with a trial scheduled for August 2026.
• Cybersecurity: In November 2025, the company experienced a security incident affecting certain sensitive information, including employee personal data.
• Supply Chain: The company relies on single or sole-source suppliers for key components (e.g., lasers, semiconductors). Qualifying alternative suppliers can take 12 to 24 months.
• Regulatory Environment: New U.S. export controls announced in January 2025 impact the export of high-parameter flow cytometers to certain countries, including China, potentially affecting sales.
• Internal Controls: Material weaknesses in internal controls identified in 2024 were remediated during 2025, and the company received an unqualified opinion on internal controls.

Investor Verification Checklist

• Valuation Allowance: Verify the assumptions behind the $33.1 million deferred tax asset valuation allowance and the likelihood of future reversals.
• Instrument Sales Trends: Investigate the 6% decline in instrument unit volumes and the impact of new export controls on the China market (which represented ~$20.5 million in revenue).
• Legal Exposure: Monitor the progress of the Beckman Coulter litigation and potential financial exposure.
• Cash Burn: Assess the sustainability of the current cash position ($261.5 million) given the shift to negative operating cash flow and continued investment in growth.
• Margin Recovery: Evaluate the timeline for gross margin recovery as the company completes the transition of its overseas manufacturing facility.